Literature DB >> 3954468

Differential effects of therapeutic regimens on specific classes of rheumatoid factor.

R M Pope, J Lessard, E Nunnery.   

Abstract

This study was performed to define further the relationship of circulating IgM and IgG rheumatoid factor to the articular manifestations of rheumatoid arthritis. Patients with substantial clinical improvement (greater than 55%) or no improvement or worsening were chosen for study. Patients were further selected to include those treated with non-steroidal anti-inflammatory drugs (NSAIDs) alone, or NSAIDs plus D-penicillamine or gold. Significant reductions of IgM (p less than 0.001) and IgG (p less than 0.005) rheumatoid factor were seen only in those treated with gold who improved clinically. These observations suggest that in patients experiencing comparable degrees of clinical improvement the simultaneous alterations of circulating IgG and IgM rheumatoid factor observed are dependent upon the therapeutic regimen employed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3954468      PMCID: PMC1001850          DOI: 10.1136/ard.45.3.183

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  23 in total

1.  Long-term chrysotherapy in rheumatoid arthritis.

Authors:  R Srinivasan; B L Miller; H E Paulus
Journal:  Arthritis Rheum       Date:  1979-02

2.  Effect of D-penicillamine on serum immunoglobulins and rheumatoid factor.

Authors:  R Bluestone; L S Goldberg
Journal:  Ann Rheum Dis       Date:  1973-01       Impact factor: 19.103

3.  Treatment of intractable rheumatoid arthritis with total lymphoid irradiation.

Authors:  B L Kotzin; S Strober; E G Engleman; A Calin; R T Hoppe; G S Kansas; C P Terrell; H S Kaplan
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

4.  Clinical and immunologic effects of fractionated total lymphoid irradiation in refractory rheumatoid arthritis.

Authors:  D E Trentham; J A Belli; R J Anderson; J A Buckley; E J Goetzl; J R David; K F Austen
Journal:  N Engl J Med       Date:  1981-10-22       Impact factor: 91.245

5.  The effect of penicillamine on the laboratory parameters in rheumatoid arthritis.

Authors:  I A Jaffe
Journal:  Arthritis Rheum       Date:  1965-12

6.  IgG rheumatoid factor, complement and immune complexes in rheumatoid synovitis and vasculitis: comparative and serial studies during cytotoxic therapy.

Authors:  D G Scott; P A Bacon; C Allen; C J Elson; T Wallington
Journal:  Clin Exp Immunol       Date:  1981-01       Impact factor: 4.330

7.  Onset, early stages, and prognosis of rheumatoid arthritis: a clinical study of 100 patients with 11-year follow-up.

Authors:  R K Jacoby; M I Jayson; J A Cosh
Journal:  Br Med J       Date:  1973-04-14

8.  Discriminatory indices of response of patients with rheumatoid arthritis treated with D-penicillamine.

Authors:  J S Dixon; M E Pickup; J R Lowe; C Hallett; M R Lee; V Wright
Journal:  Ann Rheum Dis       Date:  1980-08       Impact factor: 19.103

9.  IgG rheumatoid factor. Relationship to seropositive rheumatoid arthritis and absence in seronegative disorders.

Authors:  R M Pope; S J McDuffy
Journal:  Arthritis Rheum       Date:  1979-09

10.  IgG rheumatoid factor: analysis of various species of IgG for detection by radioimmunoassay.

Authors:  R M Pope; S J McDuffy
Journal:  J Lab Clin Med       Date:  1981-06
View more
  6 in total

1.  Significance of rheumatoid factors in an eight-year longitudinal study on arthritis.

Authors:  T Tuomi; K Aho; T Palosuo; K Kaarela; R von Essen; H Isomäki; M Leirisalo-Repo; S Sarna
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

2.  SEAPAL quality control analysis of rheumatoid factor measurement in 29 diagnostic laboratories.

Authors:  P J Roberts-Thomson; T Langhans; R McEvoy; P N Hollingsworth; E Bonifacio; R L Dawkins; J Bradley
Journal:  Ann Rheum Dis       Date:  1987-05       Impact factor: 19.103

3.  Diagnostic value and clinical significance of anti-CCP in patients with advanced rheumatoid arthritis.

Authors:  Nehir Samanci; Sebahat Ozdem; Halide Akbas; Derya Mutlu; Meral Gultekin; Mehmet Arman; Levent Donmez
Journal:  J Natl Med Assoc       Date:  2005-08       Impact factor: 1.798

Review 4.  Rational use of disease-modifying antirheumatic drugs.

Authors:  D E Furst
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

5.  Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study.

Authors:  D van Zeben; J M Hazes; A H Zwinderman; A Cats; E A van der Voort; F C Breedveld
Journal:  Ann Rheum Dis       Date:  1992-09       Impact factor: 19.103

6.  ELISA assays for IgM and IgG rheumatoid factors: their clinical correlations during therapy with slow-acting anti-rheumatic drugs.

Authors:  D L Scott; P T Dawes; M Collins; R Stone
Journal:  Clin Rheumatol       Date:  1987-09       Impact factor: 2.980

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.